Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)

Bradley F. Boeve; David W. Kimmel; Arnold E. Aronson; Piet C. De Groen

doi:10.4065/71.10.969

Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)

Bradley F. Boeve, David W. Kimmel, Arnold E. Aronson, Piet C. De Groen

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The immunosuppressive agent FK-506 (tacrolimus) is one of the agents most commonly used to prevent rejection after liver transplantation. Neurologic toxicity related to FK-506 has been reported, including speech disorders; however, a detailed analysis of the speech disorder associated with use of FK-506 has not been presented. Herein we describe a patient who exhibited mutism, then severe apraxia of speech with a concomitant hypokinetic, spastic, and ataxic dysarthria after administration of FK-506. His re-sidual mixed dysarthria, without radiographie evidence of a structural lesion, suggests dysfunction of one or more neurochemical systems. The pathophysiologic mechanisms underlying this intriguing entity remain obscure.

Original language	English (US)
Pages (from-to)	969-972
Number of pages	4
Journal	Mayo Clinic proceedings
Volume	71
Issue number	10
DOIs	https://doi.org/10.4065/71.10.969
State	Published - 1996

Keywords

Ct = computed tomography
Eeg = electroencephalography
Mri = magnetic resonance imaging

ASJC Scopus subject areas

General Medicine

Access to Document

10.4065/71.10.969

Cite this

@article{280bab13f123432a86ac07505ee94389,

title = "Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)",

abstract = "The immunosuppressive agent FK-506 (tacrolimus) is one of the agents most commonly used to prevent rejection after liver transplantation. Neurologic toxicity related to FK-506 has been reported, including speech disorders; however, a detailed analysis of the speech disorder associated with use of FK-506 has not been presented. Herein we describe a patient who exhibited mutism, then severe apraxia of speech with a concomitant hypokinetic, spastic, and ataxic dysarthria after administration of FK-506. His re-sidual mixed dysarthria, without radiographie evidence of a structural lesion, suggests dysfunction of one or more neurochemical systems. The pathophysiologic mechanisms underlying this intriguing entity remain obscure.",

keywords = "Ct = computed tomography, Eeg = electroencephalography, Mri = magnetic resonance imaging",

author = "Boeve, {Bradley F.} and Kimmel, {David W.} and Aronson, {Arnold E.} and {De Groen}, {Piet C.}",

year = "1996",

doi = "10.4065/71.10.969",

language = "English (US)",

volume = "71",

pages = "969--972",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "10",

}

TY - JOUR

T1 - Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)

AU - Boeve, Bradley F.

AU - Kimmel, David W.

AU - Aronson, Arnold E.

AU - De Groen, Piet C.

PY - 1996

Y1 - 1996

N2 - The immunosuppressive agent FK-506 (tacrolimus) is one of the agents most commonly used to prevent rejection after liver transplantation. Neurologic toxicity related to FK-506 has been reported, including speech disorders; however, a detailed analysis of the speech disorder associated with use of FK-506 has not been presented. Herein we describe a patient who exhibited mutism, then severe apraxia of speech with a concomitant hypokinetic, spastic, and ataxic dysarthria after administration of FK-506. His re-sidual mixed dysarthria, without radiographie evidence of a structural lesion, suggests dysfunction of one or more neurochemical systems. The pathophysiologic mechanisms underlying this intriguing entity remain obscure.

AB - The immunosuppressive agent FK-506 (tacrolimus) is one of the agents most commonly used to prevent rejection after liver transplantation. Neurologic toxicity related to FK-506 has been reported, including speech disorders; however, a detailed analysis of the speech disorder associated with use of FK-506 has not been presented. Herein we describe a patient who exhibited mutism, then severe apraxia of speech with a concomitant hypokinetic, spastic, and ataxic dysarthria after administration of FK-506. His re-sidual mixed dysarthria, without radiographie evidence of a structural lesion, suggests dysfunction of one or more neurochemical systems. The pathophysiologic mechanisms underlying this intriguing entity remain obscure.

KW - Ct = computed tomography

KW - Eeg = electroencephalography

KW - Mri = magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=0030317448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030317448&partnerID=8YFLogxK

U2 - 10.4065/71.10.969

DO - 10.4065/71.10.969

M3 - Article

C2 - 8820772

AN - SCOPUS:0030317448

SN - 0025-6196

VL - 71

SP - 969

EP - 972

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 10

ER -

Dysarthria and apraxia of speech associated with FK-506 (Tacrolimus)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this